BioNTech Shifts to Oncology Amid Leadership Transition and Stock Volatility

Key Facts

1BioNTech plans to have 15 ongoing Phase 3 oncology trials by the end of 2026.

2Morgan Stanley set a price target of $128 for BioNTech, suggesting a potential 52.58% upside.

3Co-founders Ugur Sahin and Özlem Türeci are launching a new venture, which contributed to a 21% drop in share price.

4The company maintains a strong financial position with €17.2 billion in cash despite a net loss of €1.14 billion for 2025.

BioNTech SE is strategically pivoting its focus toward oncology and next-generation mRNA technology as it transitions from its COVID-19 vaccine success. The company aims to have 15 ongoing Phase 3 clinical trials in the oncology sector by the end of 2026. Despite a projected net loss of €1.14 billion for 2025, BioNTech maintains a robust financial position with €17.2 billion in cash reserves. Morgan Stanley has set a bullish price target of $128 for the stock, implying a potential upside of over 52%. However, the departure of co-founders Ugur Sahin and Özlem Türeci to launch a new venture has triggered a 21% decline in share price. This leadership transition creates a period of uncertainty even as the firm pursues long-term growth in cancer treatment.